Asegua Therapeutics — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Asegua Therapeutics is a specialized generic pharmaceutical company established as an affiliate of Gilead Sciences to enhance patient access to high-cost hepatitis C treatments. Its core business involves launching and distributing authorized generic versions of Gilead's blockbuster drugs EPCLUSA® and HARVONI®, which are direct-to-generic copies sold under the Asegua label. The company operates within Gilead's ecosystem, leveraging the originator's manufacturing and support infrastructure while offering the drugs at a lower price point. Its mission is strategically aligned with addressing payer and patient affordability concerns in the HCV market.

Infectious DiseaseHepatitis C

Technology Platform

Commercial and regulatory model for launching authorized generic versions of Gilead's patented direct-acting antiviral drugs. No proprietary drug discovery platform.

Opportunities

The primary opportunity is to increase treatment access in price-sensitive payer channels like Medicaid, corrections, and the VA by offering lower-cost, authorized generic versions of curative HCV therapies.

This model also allows parent company Gilead to retain market share and revenue that might otherwise be lost to independent generic competitors following patent expiry.

Risk Factors

Key risks include intense competition from lower-priced, non-authorized generic entrants following patent expirations, a declining prevalent HCV patient pool in the U.S., and complete strategic and operational dependency on Gilead Sciences.

Further government drug pricing reforms could also pressure the authorized generic pricing model.

Competitive Landscape

Asegua competes in the generic HCV market, facing direct competition from independent generic manufacturers (e.g., Mylan, Teva) offering bioequivalent versions of sofosbuvir-based regimens, often at very low prices. It also competes indirectly with other branded HCV therapies, though the market is now dominated by generics. Its key advantage is being an 'authorized generic' with guaranteed product identity to the brand.

More companies in Small Molecule Drugs →More companies in United States →